NASDAQ:OCX

OncoCyte (OCX) Stock Forecast, Price & News

$0.22

-0.01 (-4.36%)

(As of 06/2/2023 ET)

Compare

Today's Range: $0.21
▼
$0.23
50-Day Range: $0.21
▼
$0.27
52-Week Range: $0.20
▼
$1.35

Volume: 369,127 shs
Average Volume: 233,045 shs
Market Capitalization: $36.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.11

OncoCyte MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 406.6% Upside
$1.11 Price Target
Short Interest: Healthy
0.70% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.16
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$8.25 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.28) to ($0.27) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

209th out of 983 stocks

Diagnostic Substances Industry

6th out of 15 stocks

3.2

Analyst's Opinion

Consensus Rating
OncoCyte has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.11, OncoCyte has a forecasted upside of 406.6% from its current price of $0.22.
Amount of Analyst Coverage
OncoCyte has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.70% of the outstanding shares of OncoCyte have been sold short.
Short Interest Ratio / Days to Cover
OncoCyte has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in OncoCyte has recently decreased by 2.52%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
OncoCyte does not currently pay a dividend.
Dividend Growth
OncoCyte does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OCX.

1.8

News and Social Media Coverage

News Sentiment
OncoCyte has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for OncoCyte this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for OCX on MarketBeat in the last 30 days. This is a decrease of -95% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,247,191.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.65% of the stock of OncoCyte is held by insiders.
Percentage Held by Institutions
81.20% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for OncoCyte are expected to grow in the coming year, from ($0.28) to ($0.27) per share.
Price to Book Value per Share Ratio
OncoCyte has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About OncoCyte (NASDAQ:OCX) Stock

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Stock News Headlines

June 3, 2023 | americanbankingnews.com

OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

June 1, 2023 | finance.yahoo.com

Oncocyte Corporation to Present at the LD Micro Invitational XIII

June 4, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 28, 2023 | americanbankingnews.com

OncoCyte (NYSE:OCX) Research Coverage Started at StockNews.com

May 28, 2023 | americanbankingnews.com

OncoCyte (NYSE:OCX) Now Covered by Analysts at StockNews.com

May 11, 2023 | finanznachrichten.de

Oncocyte Corporation: Oncocyte Reports First Quarter 2023 Financial Results

May 11, 2023 | finance.yahoo.com

Oncocyte Reports First Quarter 2023 Financial Results

May 10, 2023 | msn.com

OncoCyte Q1 2023 Earnings Preview

June 4, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.

May 9, 2023 | americanbankingnews.com

OncoCyte (OCX) to Release Earnings on Thursday

May 8, 2023 | americanbankingnews.com

OncoCyte (NYSE:OCX) Receives New Coverage from Analysts at StockNews.com

May 2, 2023 | americanbankingnews.com

OncoCyte (NYSE:OCX) Coverage Initiated at StockNews.com

April 27, 2023 | finance.yahoo.com

Oncocyte To Announce First Quarter 2023 Financial Results

April 27, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on OncoCyte (NYSE:OCX)

April 19, 2023 | americanbankingnews.com

OncoCyte (NYSE:OCX) Now Covered by StockNews.com

April 18, 2023 | finance.yahoo.com

Oncocyte Presents New Data at AACR

April 13, 2023 | msn.com

Oncocyte's Announces Another Round Of Layoffs Leaving 20% Of Staff Impacted

April 12, 2023 | markets.businessinsider.com

Oncocyte Reduces Workforce By 20%

April 12, 2023 | finance.yahoo.com

Oncocyte Announces Reduction in Force

April 12, 2023 | 247wallst.com

Broadwood Partners Now Owns 33.3% of OncoCyte

April 10, 2023 | finance.yahoo.com

OncoCyte Corporation (NASDAQ:OCX) Q4 2022 Earnings Call Transcript

April 9, 2023 | nasdaq.com

Broadwood Partners Now Owns 33.30% of OncoCyte (OCX)

April 8, 2023 | americanbankingnews.com

OncoCyte Co. (NASDAQ:OCX) Major Shareholder Pura Vida Investments, Llc Buys 663,000 Shares of Stock

April 8, 2023 | americanbankingnews.com

OncoCyte Co. (NASDAQ:OCX) Major Shareholder Broadwood Partners, L.P. Acquires 26,827,638 Shares

April 7, 2023 | finance.yahoo.com

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

April 6, 2023 | americanbankingnews.com

OncoCyte (NASDAQ:OCX) PT Lowered to $0.45

April 3, 2023 | finance.yahoo.com

Oncocyte Pricing of $13.86 Million Public Offering of Common Stock

See More Headlines

OCX Price History

30 days | 90 days | 365 days | Advanced Chart

OCX Company Calendar

Last Earnings: 11/09/2021
Today: 6/03/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OCX
CUSIP: N/A
CIK: 1642380
Web: oncocyte.com
Phone: (949) 409-7600
Fax: 510-521-3389
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $1.11
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $0.45
Forecasted Upside/Downside: +406.6%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-72,900,000.00
Net Margins: -787.97%
Pretax Margin: -1,056.00%
Return on Equity: -34.08%
Return on Assets: -15.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.66
Quick Ratio: 1.66

Sales & Book Value

Annual Sales: $960,000.00
Price / Sales: 37.70
Cash Flow: $0.04 per share
Price / Cash Flow: 5.09
Book Value: $0.32 per share
Price / Book: 0.69

Miscellaneous

Outstanding Shares: 164,820,000
Free Float: 111,347,000
Market Cap: $36.19 million
Optionable: Optionable
Beta: 1.58

Key Executives

Joshua Riggs
President, Chief Executive Officer & Director

Anish John
Chief Financial Officer & Senior Vice President

Ekkehard Schütz
Chief Science Officer

Yuh-Min Chiang
Senior Vice President-Research & Development

Padma Sundar
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OCX Stock - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OCX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCX, but not buy additional shares or sell existing shares.
View OCX analyst ratings or view top-rated stocks.
What is OncoCyte's stock price forecast for 2023?: 3 analysts have issued 12 month price targets for OncoCyte's stock. Their OCX share price forecasts range from $0.45 to $3.00. On average, they anticipate the company's share price to reach $1.11 in the next year. This suggests a possible upside of 406.6% from the stock's current price.
View analysts price targets for OCX or view top-rated stocks among Wall Street analysts.
How have OCX shares performed in 2023?: OncoCyte's stock was trading at $0.3209 on January 1st, 2023. Since then, OCX stock has decreased by 31.6% and is now trading at $0.2196.
View the best growth stocks for 2023 here.
When is OncoCyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our OCX earnings forecast.
How were OncoCyte's earnings last quarter?: OncoCyte Co. (NASDAQ:OCX) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The company earned $0.98 million during the quarter, compared to analyst estimates of $3.20 million. OncoCyte had a negative net margin of 787.97% and a negative trailing twelve-month return on equity of 34.08%.
What other stocks do shareholders of OncoCyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN).

What is OncoCyte's stock symbol?: OncoCyte trades on the NASDAQ under the ticker symbol "OCX."
Who are OncoCyte's major shareholders?: OncoCyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Defender Capital LLC. (1.98%). Insiders that own company stock include Albert P Parker, Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Mitchell S Levine, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends.
How do I buy shares of OncoCyte?: Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is OncoCyte's stock price today?: One share of OCX stock can currently be purchased for approximately $0.22.
How much money does OncoCyte make?: OncoCyte (NASDAQ:OCX) has a market capitalization of $36.19 million and generates $960,000.00 in revenue each year.
How can I contact OncoCyte?: OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.

This page (NASDAQ:OCX) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial